tbuckley/cabot-search huggingface dataset:
Combinations of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kdelta) Inhibitor GS–1101 (CAL-101) with Rituximab and/or Bendamustine Are Tolerable and Highly Active in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Results From a Phase I Study
Authors: Steven E. Coutre, John P. Leonard, Richard R. Furman, Jacqueline C. Barrientos, Sven de Vos, Ian W. Flinn, Marshall T. Schreeder, Nina D. Wagner-Johnston, Jeff Sharman, Thomas E. Boyd, Nathan H Fowler, Leanne M. Holes, Brian J. Lannutti, Dave M. Johnson, Langdon L Miller, Thomas M. Jahn
Journal: Blood (2012)
No Significant Improvement In the Outcome of Patients with Waldenström's Macroglobulinemia Treated Over the Last 25 Years
Authors: Efstathios Kastritis, Marie-Christine Kyrtsonis, Evdoxia Hadjiharissi, Argiris Symeonidis, Eurydiki Michalis, Panagiotis Repoussis, Konstantinos Tsatalas, Michael Michael, Anastasia Sioni, Zafiris Kartasis, Ekaterini Stefanoudaki, Michael Voulgarelis, Sosana Delimpasi, Maria Gavriatopoulou, Efstathios Koulieris, Dimitra Gika, Elissavet Vervesou, Konstantinos Konstantopoulos, Garyfalia Kokkini, Athanasios Zomas, Paraskevi Roussou, Nikolaos Anagnostopoulos, Theofanis Economopoulos, Evangelos Terpos, Konstantinos Zervas, Meletios A. Dimopoulos
Journal: Blood (2010)
Iterative Germinal Center Re-Entries of Memory B-Cells with t(14;18) Translocation and Early Steps of Follicular Lymphoma Progression
Authors: Sandrine Roulland, Jocelyne Stephanie Sungalee, Ester Morgado, Emilie Mamessier, Emilie Gregoire, Celine Monvoisin, Cedric Menard, Jean-Marc Navarro, Franziska C. Eberle, Philippe Ruminy, Elaine S. Jaffe, Claudine Schiff, Jean Hardwigsen, Karin Tarte, Bertrand Nadel
Journal: Blood (2012)
5-Azacitidine Plus Vorinostat As Maintenance Therapy of Second Remission in AML Instead of High Doses of Consolidation with Cytarabine
Authors: Roberto Ovilla, Claudia Barrera-Carmona, Nicolas Guzman-Bouilloud, Elizabeth Buganza-Torio, Rosa Jimenez-Alvarado, Claudia Monreal-Alcantara
Journal: Blood (2012)
Epigenetic Modifying Drugs Inhibit MDS/AML Cell Growth through Selective Disruption of the Interactions Between Lineage-Determining Transcription Factors and DNA/Histone Modifiers
Authors: Yuan Li, Ming Yue, John Anastasi, Jeffery Q Shen, Yali Dou, Richard A. Larson, James W. Vardiman, Jason X. Cheng
Journal: Blood (2015)
Evaluating Hospital-Based Surveillance for Outbreak Detection in Bangladesh: Analysis of Healthcare Utilization Data
Authors: Birgit Nikolay, Henrik Salje, Katharine Sturm-Ramirez, Eduardo Azziz-Baumgartner, Nusrat Homaira, Makhdum Ahmed, A. Danielle Iuliano, Repon C. Paul, Mahmudur Rahman, M. Jahangir Hossain, Stephen P. Luby, Simon Cauchemez, Emily S. Gurley
Journal: PLoS Medicine (2017)

The International Health Regulations outline core requirements to ensure the detection of public health threats of international concern. Assessing the capacity of surveillance systems to detect these threats is crucial for evaluating a country's ability to meet these requirements.We propose a framework to evaluate the sensitivity and representativeness of hospital-based surveillance and apply it to severe neurological infectious diseases and fatal respiratory infectious diseases in Bangladesh. We identified cases in selected communities within surveillance hospital catchment areas using key informant and house-to-house surveys and ascertained where cases had sought care. We estimated the probability of surveillance detecting different sized outbreaks by distance from the surveillance hospital and compared characteristics of cases identified in the community and cases attending surveillance hospitals. We estimated that surveillance detected 26% (95% CI 18%-33%) of severe neurological disease cases and 18% (95% CI 16%-21%) of fatal respiratory disease cases residing at 10 km distance from a surveillance hospital. Detection probabilities decreased markedly with distance. The probability of detecting small outbreaks (three cases) dropped below 50% at distances greater than 26 km for severe neurological disease and at distances greater than 7 km for fatal respiratory disease. Characteristics of cases attending surveillance hospitals were largely representative of all cases; however, neurological disease cases aged <5 y or from the lowest socioeconomic group and fatal respiratory disease cases aged ≥60 y were underrepresented. Our estimates of outbreak detection rely on suspected cases that attend a surveillance hospital receiving laboratory confirmation of disease and being reported to the surveillance system. The extent to which this occurs will depend on disease characteristics (e.g., severity and symptom specificity) and surveillance resources.We present a new approach to evaluating the sensitivity and representativeness of hospital-based surveillance, making it possible to predict its ability to detect emerging threats.
Why would I smile?
Authors: Kaustubh G Joshi
Journal: BMJ (2017)

“Why won’t you smile?” I asked my patient after several weeks of treating his psychotic symptoms. Although he reported an improvement in his mood and feeling more upbeat compared with when he was admitted, he never smiled. His answer was profound: “Look at my teeth. I barely have any left, and whatever is left looks gross. Why would I smile?”

Dental …
Inhibition of Prostaglandin E2 (PGE2) Signaling by Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) or EP4 Receptor Antagonism Expands Hematopoietic Stem and Progenitor Cells (HSPC) and Enhances Their Mobilization to Peripheral Blood in Mice and Baboons.
Authors: Jonathan Hoggatt, Pratibha Singh, Amber Hoggatt, Jennifer M. Speth, Louis M. Pelus
Journal: Blood (2009)
High Levels of CD34 Expression in Bone Marrow Trephines Predicts for Loss of Cytogenetic Response in Patients with in Chronic Phase Who Have Achieved Complete Cytogenetic Remission on Imatinib Therapy.
Authors: David Marin, D. Horncastle, Jill Howard, Catherina Andreasson, V. Elliot, Jonh M. Goldman, Jane F. Apperley, Kikkeri Naresh, Irvin Lampert
Journal: Blood (2004)
Roles of Thromboxane A2 On High Salt Induced-Fetal Defect.
Authors: Chen-Hsueh Pai, Shu-Wha Lin, I-Shing Yu, Ching-Tzu Yen, Yung-Li Yang, Shiann-Tarng Jou, Dong-Tsamn Lin, Jiann-Shiuh Chen, Shu-Rung Lin
Journal: Blood (2009)
Incidence of Sinusoidal Obstruction Syndrome Following Mylotarg (Gemtuzumab Ozogamicin, GO): a Prospective Observational Study in Routine Clinical Practice.
Authors: Marti n S Tallman, George B McDonald, Laurie D DeLeve, Eliot Obi-Tabot, Carl Kollmer, Jay M Feingold
Journal: Blood (2008)
Efficacy of Focal Adhesion Kinase Inhibition in Combination with Dasatinib in BCR-ABL1 Acute Lymphoblastic Leukemia
Authors: Michelle L. Churchman, Luke Jones, Kathryn Evans, Jennifer Richmond, Irina M Shapiro, Jonathan A. Pachter, David T. Weaver, Peter J Houghton, Malcolm A. Smith, Richard B Lock, Charles G. Mullighan
Journal: Blood (2015)
Oral Clofarabine in the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome.
Authors: Stefan Faderl, Guillermo Garcia-Manero, Zeev Estrov, Farhad Ravandi, Gautam Borthakur, Jorge Cortes, Susan O'Brien, Varsha Gandhi, William Plunkett, Anna L. Byrd, Monica Kwari, Hagop Kantarjian
Journal: Blood (2009)
Long Noncoding RNA LINC00092 Acts in Cancer-Associated Fibroblasts to Drive Glycolysis and Progression of Ovarian Cancer
Authors: Linjie Zhao, Gaili Ji, Xiaobing Le, Chenlu Wang, Lian Xu, Min Feng, Yaguang Zhang, Huiliang Yang, Yu Xuan, Yanfei Yang, Lingzi Lei, Qilian Yang, Wayne Bond Lau, Bonnie Lau, Yi Chen, Xiangbing Deng, Shaohua Yao, Tao Yi, Xia Zhao, Yuquan Wei, Shengtao Zhou
Journal: Cancer Research (2017)

Abstract The majority of patients with epithelial ovarian cancer are diagnosed at a late stage when the peritoneal metastases exist; however, there is little knowledge of the metastatic process in this disease setting. In this study, we report the identification of the long noncoding RNA LINC00092 as a nodal driver of metastatic progression mediated by cancer-associated fibroblasts (CAF). Prometastatic properties of CAFs in vitro and in vivo were found to associate with elevated expression of the chemokine CXCL14. In clinical specimens, elevated levels of CXCL14 in CAFs also correlated with poor prognosis. Notably, CXCL14-high CAFs mediated upregulation of LINC00092 in ovarian cancer cells, the levels of which also correlated with poor prognosis in patients. Mechanistic studies showed that LINC00092 bound a glycolytic enzyme, the fructose-2,6-biphosphatase PFKFB2, thereby promoting metastasis by altering glycolysis and sustaining the local supportive function of CAFs. Overall, our study uncovered a positive feedback loop in the metabolism of CXCL14-positive CAFs and ovarian cancer cells that is critical for metastatic progression. Cancer Res; 77(6); 1369–82. ©2017 AACR.
Autophagy of ER-Retained Mpl Is Linked to Low Expression Levels of Jak2 and Provides an Unconventional Route to Cell Surface.
Authors: Cédric Cleyrat, Anza Darehshouri, Mathias Vilaine, Mara P. Steinkamp, Daniela Boassa, Mark H Ellisman, Sylvie Hermouet, Bridget S Wilson
Journal: Blood (2012)
Long-term Postprocedural Outcomes of Palliative Emergency Stenting vs Stoma in Malignant Large-Bowel Obstruction
Authors: Jonathan S. Abelson, Heather L. Yeo, Jialin Mao, Jeffrey W. Milsom, Art Sedrakyan
Journal: JAMA Surgery (2017)

Colonic stenting was introduced for palliation of malignant large-bowel obstruction (MLBO) more than 20 years ago but remains controversial.To compare outcomes after palliative stenting vs stoma creation in patients with MLBO requiring emergency management.This observational cohort study assessed 345 patients from New York State with an urgent or emergency admission to the hospital for obstruction secondary to colorectal cancer and who underwent stenting or stoma creation from October 1, 2009, through December 31, 2013. Patients were excluded if they underwent resection within 1 year of the index admission.Palliative stenting vs stoma creation.Primary outcomes included subsequent operation and readmission within 90-day and 1-year follow-up. Secondary outcomes were in-hospital death, major medical and surgical complications, length of stay, total charges, and discharge dispositions. Multivariable hierarchical analyses and propensity score matching were used to compare outcomes between the exposure groups.The cohort included 345 patients (mean [SD] age, 69.9 [14.4] years in the stoma group and 70.9 [16.8] years in the stent group; 87 men [50.3%] in the stoma group and 90 [52.3%] in the stent group; and 114 non-Hispanic white patients [65.9%] in the stoma group and 90 [52.3%] in the stent group). Most patients undergoing stenting were treated at high-volume (104 [60.5%]) vs medium-volume (42 [24.4%]) or low-volume (26 [15.1%]) hospitals (P < .001). Patients undergoing stenting were significantly less likely to experience prolonged length of stay (odds ratio [OR], 0.50; 95% CI, 0.26-0.97; P = .04), more likely to be discharged to their usual residence (OR, 0.14; 95% CI, 0.07-0.28; P < .001), and tended to have similar or fewer complications (major events: OR, 0.81; 95% CI, 0.30-2.18; P = .68; procedural complications: OR, 0.57; 95% CI, 0.11-1.22; P = .10). There was no significant difference between the groups in terms of 90-day and 1-year readmission to the hospitals (90 days: OR, 0.93; 95% CI, 0.49-1.78; P = .83; 1 year: OR, 0.72; 95% CI, 0.38-1.37; P = .30). Subsequent operation at 90 days was also not different between the groups (OR, 1.34; 95% CI, 0.26-6.89; P = .72), but there was a higher chance of subsequent operation at 1 year after the stenting procedure (OR, 2.93; 95% CI, 1.12-7.68; P = .03), with most subsequent operations being restenting.In patients with MLBO and if resection is not part of the treatment plan, stenting is safe and improves the efficiency of care with obvious quality-of-life benefits. It should be offered at experienced centers, and patients should be counseled regarding increased risk of subsequent stenting within 1 year.
What is the benefit of early follow‐up after hospitalization for patients with cirrhosis?
Authors: Robert Driver, Ian A. Rowe
Journal: Hepatology (2017)

Potential conflict of interest: Nothing to report. TO THE EDITOR: We read with interest the recently published paper by Kanwal et al. This retrospective cohort study identifies an association between early outpatient follow‐up in patients recently hospitalized with cirrhosis and lower overall mortality within 30 days of discharge.1 The absolute reduction in mortality is 2%. This means that approximately 50 patients would need to be reviewed in the first week after discharge to prevent one early death if the results are taken at face value. Given this small absolute difference in mortality, it is critical to note the potential limitations in the data. The data analyzed are from a large administrative data set that has inherent limitations, particularly in the depth of information available. For instance, the researchers acknowledge that data on Model for End‐Stage Liver Disease (MELD) were not available for 20% of patients included in the propensity score analysis. Additionally, it is likely that there are unmeasured variables within the data set. For example, behaviors such as ongoing excessive alcohol consumption might simultaneously predispose a patient not to attend scheduled follow‐up visits and increase the risk of mortality. Although sensitivity analyses can address missing data such as MELD to some extent, by definition unmeasured variables cannot be assessed and may be confounding in the analyses. The other issue that is difficult to address is that it is not known why some patients received early follow‐up and others did not. The two cohorts were created retrospectively by clinic attendance, so the nonattendance rate at a planned follow‐up visit in the first 7 days after hospital discharge is not known. It is plausible that the mortality in patients who are unable to attend scheduled visits is higher than those patients who do attend despite being well matched in all other regards. The substantially higher rates of mortality in those patients not attending for an early follow‐up visit on days 8‐15 after discharge might support that hypothesis. The findings of this retrospective study highlight an important issue in the management of patients with cirrhosis discharged from the hospital, but they do not provide definitive evidence of the benefits of early outpatient follow‐up. Prospective, randomized evaluations of early follow‐up and transitional care arrangements will provide a clearer estimate of the benefits of this approach.
Rituximab Is Associated with Prolonged Immunoglobulin Deficiency In Newly Diagnosed Patients with Aggressive B-Cell Lymphoma Receiving Immunochemotherapy
Authors: Kieron Dunleavy, Benjamin L.W. Reiter, Cliona M. Grant, Margaret Shovlin, George W. Wright, Thomas A. Fleisher, Wyndham H. Wilson
Journal: Blood (2010)
Racial Differences in Prognostic Factors and Outcomes in Patients Undergoing Allogeneic Hematopoietic Cell Transplant
Authors: Betty K. Hamilton, Lisa Rybicki, Mikkael A. Sekeres, Brian J. Bolwell, Matt Kalaycio, Rabi Hanna, Robert M Dean, Ronald Sobecks, Hien K. Duong, Brian T. Hill, Edward A. Copelan
Journal: Blood (2012)
Escalation Trial of Clofarabine Followed by Escalating Dose of Fractionated Cyclophosphamide in Adults with Relapsed or Refractory Acute Leukemias,
Authors: Amer M. Zeidan, Hetty E Carraway, Hyun Don Yun, Jacqueline M Greer, Judith E. Karp
Journal: Blood (2011)
Prostate Cancer Patients with Late Radiation Toxicity Exhibit Reduced Expression of Genes Involved in DNA Double-Strand Break Repair and Homologous Recombination
Authors: Bregje van Oorschot, Lon Uitterhoeve, Ilja Oomen, Rosemarie ten Cate, Jan Paul Medema, Harry Vrieling, Lukas J.A. Stalpers, Perry D. Moerland, Nicolaas A.P. Franken
Journal: Cancer Research (2017)

Severe late damage to normal tissue is a major limitation of cancer radiotherapy in prostate cancer patients. In a recent retrospective study, late radiation toxicity was found to relate to a decreased decay of γ-H2AX foci and reduced induction of DNA double-strand break repair genes. Here, we report evidence of prognostic utility in prostate cancer for γ-H2AX foci decay ratios and gene expression profiles derived from ex vivo-irradiated patient lymphocytes. Patients were followed ≥2 years after radiotherapy. Clinical characteristics were assembled, and toxicity was recorded using the Common Terminology Criteria (CTCAE) v4.0. No clinical factor was correlated with late radiation toxicity. The γ-H2AX foci decay ratio correlated negatively with toxicity grade, with a significant difference between grade ≥3 and grade 0 patients (P = 0.02). A threshold foci decay ratio, determined in our retrospective study, correctly classified 23 of 28 patients with grade ≥3 toxicity (sensitivity 82%) and 9 of 14 patients with grade 0 toxicity (specificity 64%). Induction of homologous recombination (HR) repair genes was reduced with increasing toxicity grade. The difference in fold induction of the HR gene set was most pronounced between grade 0 and grade ≥3 toxicity (P = 0.008). Notably, reduced responsiveness of HR repair genes to irradiation and inefficient double-strand break repair correlated with severe late radiation toxicity. Using a decay ratio classifier, we correctly classified 82% of patients with grade ≥3 toxicity, suggesting a prognostic biomarker for cancer patients with a genetically enhanced risk for late radiation toxicity to normal tissues after radiotherapy. Cancer Res; 77(6); 1485-91. ©2017 AACR.
SOX11 Expression Versus Indolent Clinical Course in Mantle Cell Lymphomas in a Population-Based Cohort From the Stockholm Region – SOX11 Negative Tumors Are Mostly p53 Positive, Contributing to Shorter Overall Survival,
Authors: Birgitta Sander, Monika Klimkowska, Lina Nygren, Stefanie Baumgartner, Birger Christensson, Eva Kimby
Journal: Blood (2011)
Effectiveness of flexible sigmoidoscopy screening in men and women and different age groups: pooled analysis of randomised trials
Authors: Øyvind Holme, Robert E Schoen, Carlo Senore, Nereo Segnan, Geir Hoff, Magnus Løberg, Michael Bretthauer, Hans-Olov Adami, Mette Kalager
Journal: BMJ (2017)

<b>Objective</b>&nbsp;To compare the effectiveness of flexible sigmoidoscopy in screening for colorectal cancer by patient sex and age. <b>Design</b>&nbsp;Pooled analysis of randomised trials (the US Prostate, Lung, Colorectal and Ovarian cancer screening trial (PLCO), the Italian Screening for Colon and Rectum trial (SCORE), and the Norwegian Colorectal Cancer Prevention trial (NORCCAP)). <b>Data sources</b>&nbsp;Aggregated data were pooled from each randomised trial on incidence of colorectal cancer and mortality stratified by sex, age at screening, and colon subsite (distal <i>v</i> proximal). <b>Eligibility criteria for selecting studies</b>&nbsp;Invited individuals aged 55-74 (PLCO), 55-64 (SCORE), and 50-64 (NORCCAP). Individuals were randomised to receive flexible sigmoidoscopy screening once only (SCORE and NORCCAP) or twice (PLCO), or receive usual care (no intervention). <b>Results</b>&nbsp;287 928 individuals were included in the pooled analysis; 115 139 randomised to screening and 172 789 to usual care. Compliance rates were 58%, 63%, and 87% in SCORE, NORCCAP, and PLCO, respectively. Median follow-up was 10.5 to 12.1 years. Screening reduced the incidence of colorectal cancer in men (relative risk 0.76; 95% confidence interval 0.70 to 0.83) and women (0.83; 0.75 to 0.92). No difference in the effect of screening was seen between men younger than 60 and those older than 60. Screening reduced the incidence of colorectal cancer in women younger than 60 (relative risk 0.71; 95% confidence interval 0.59 to 0.84), but not significantly in those aged 60 or older (0.90; 0.80 to 1.02). Colorectal cancer mortality was significantly reduced in both younger and older men, and in women younger than 60. Screening reduced colorectal cancer incidence to a similar extent in the distal colon in men and women, but there was no effect of screening in the proximal colon in older women with a significant interaction between sex and age group (P=0.04). <b>Conclusion</b>&nbsp;Flexible sigmoidoscopy is an effective tool for colorectal cancer screening in men and younger women. The benefit is smaller and not statistically significant for women aged over 60; alternative screening methods that more effectively detect proximal tumours should be considered for these women.
Effective Targeting of Leukemic Cells in Children with B-Precursor Acute Lymphoblastic Leukemia Treated with Anti-CD22 (Epratuzumab). A Children’s Oncology Group (COG) Study.
Authors: Michael J. Borowitz, William L. Carroll, Peter C. Adamson, Mitchell S. Cairo, David M. Goldenberg, William A. Wegener, Elizabeth Raetz
Journal: Blood (2006)
Zygomycosis: A Severe Fungal Infection with Challenging Diagnostic Difficulties: A Case with Cardiac Involvement without Cardiac Symptoms.
Authors: Maria I.A. Madeira, Maria C. Favarin, Leonardo C. Palma, George M.N. Barros, Cristina A. Souza, Clarisse M. Machado, Julio C. Voltarelli, Ana B.P.L. Stracieri, Belinda P. Simoes
Journal: Blood (2007)
Bombesin Antagonist-Based Radiotherapy of Prostate Cancer Combined with WST-11 Vascular Targeted Photodynamic Therapy
Authors: Kwanghee Kim, Hanwen Zhang, Stephen La Rosa, Sylvia Jebiwott, Pooja Desai, Simon Kimm, Avigdor Scherz, Joseph A. O'Donoghue, Wolfgang A. Weber, Jonathan A. Coleman
Journal: Clinical Cancer Research (2017)

Purpose: DOTA-AR, a bombesin-antagonist peptide, has potential clinical application for targeted imaging and therapy in gastrin-releasing peptide receptor (GRPr)-positive malignancies when conjugated with a radioisotope such as 90Y. This therapeutic potential is limited by the fast washout of the conjugates from the target tumors. WST-11 (Weizmann STeba-11 drug; a negatively charged water-soluble palladium-bacteriochlorophyll derivative, Tookad Soluble) vascular targeted photodynamic therapy (VTP) is a local ablation approach recently approved for use in early-stage prostate cancer. It generates reactive oxygen/nitrogen species within tumor blood vessels, resulting in their instantaneous destruction followed by rapid tumor necrosis. We hypothesize that the instantaneous arrest of tumor vasculature may provide a means to trap radiopharmaceuticals within the tumor, thereby improving the efficacy of targeted radiotherapy.Experimental Design: GRPr-positive prostate cancer xenografts (PC-3 and VCaP) were treated with 90Y-DOTA-AR with or without VTP. The uptake of radioisotopes was monitored by Cherenkov luminescence imaging (CLI). The therapeutic efficacy of the combined VTP and 90Y-DOTA-AR in PC-3 xenografts was assessed.Results: CLI of 90Y-DOTA-AR demonstrated longer retention of radiotracer within the VTP-treated PC-3 xenografts compared with the non-VTP-treated ones (P < 0.05) at all time points (24-144 hours) after 90Y-DOTA-AR injection. A similar pattern of retention was observed in VCaP xenografts. When 90Y-DOTA-AR administration was combined with VTP, tumor growth delay was significantly longer than for the control or the monotherapy groups.Conclusions: Tumor vascular arrest by VTP improves 90Y-DOTA-AR retention in the tumor microenvironment thereby enhancing therapeutic efficacy. Clin Cancer Res; 23(13); 3343-51. ©2017 AACR.
Signal Transducer and Activator of Transcription (STAT)-3 Induces the Expression of Microrna-155 in Chronic Lymphocytic Leukemia (CLL) Cells.
Authors: Ping Li, Srdana Grgurevic, Zhiming Liu, David Harris, Uri Rozovski, Michael J. Keating, George Calin, Zeev Estrov
Journal: Blood (2012)
Adapting to the global shortage of cholera vaccines: targeted single dose cholera vaccine in response to an outbreak in South Sudan
Authors: Lucy A Parker, John Rumunu, Christine Jamet, Yona Kenyi, Richard Laku Lino, Joseph F Wamala, Allan M Mpairwe, Iza Ciglenecki, Francisco J Luquero, Andrew S Azman, Jean-Clement Cabrol
Journal: The Lancet Infectious Diseases (2017)